BioStem (BSEM) CCO Barry Hassett Exercises Options (500 Acq / 500 Disp)

What Happened

• Barry Hassett, Chief Commercial Officer of BioStem Technologies (BSEM), reported an exercise/conversion of a derivative (Form 4 transaction code M) on 2026-09-09. The filing shows he acquired 500 shares at $0.00 per share and concurrently disposed of 500 shares at $0.00 per share. The filing reports no cash value for these entries (total value $0).

Key Details

• Transaction date: 2026-09-09; Form 4 filed: 2026-09-11 (timely filing).
• Transactions reported: 500 shares acquired (M) @ $0.00; 500 shares disposed (M/derivative) @ $0.00.
• Reported transaction value: $0 (no cash proceeds or purchase price shown in the excerpt).
• Shares owned after the transaction: not provided in the excerpt supplied.
• Footnotes in the filing (F1–F7) describe various vesting schedules for options and restricted stock units and note that each RSU represents a contingent right to one share (F4); several footnotes specify one‑year cliff vesting followed by quarterly vesting schedules.
• No 10b5-1 plan, tax withholding, or other sale-plan language was cited in the provided summary.

Context

• Transaction code M means an exercise or conversion of a derivative (for example, an option conversion or RSU settlement). The filing shows an acquisition and an immediate disposition of the same number of shares at $0; the document does not show cash exchanged. For retail investors: outright purchases (cash buys) are often stronger signals of personal bullishness; conversions/settlements and internal transfers can be routine compensation or vesting-related events and do not necessarily indicate a change in insider sentiment.